Medication · US & Canada
Oral semaglutide (Rybelsus, Wegovy pill), explained
By Joshua Nichvolodoff · Fact-checked against sources November 2, 2026 · Next review due May 1, 2027
Clinical review: not yet reviewed by a clinician. How review works · Editorial policy
Semaglutide also comes as a once-daily tablet. In the US there are three tablet products — Rybelsus and Ozempic tablets for type 2 diabetes, and Wegovy tablets for weight management[1][2].
Status in the US and Canada
| Item | United States | Canada |
|---|---|---|
| Rybelsus | Type 2 diabetes; lower risk of major heart events in type 2 diabetes at high risk | Type 2 diabetes; lower risk of major heart events in type 2 diabetes |
| Ozempic tablets | Type 2 diabetes (shares the Rybelsus label) | Not under this name; the Rybelsus monograph lists 1.5, 4 and 9 mg tablets |
| Wegovy tablets | Weight management; heart risk | Applied for (Dec 2025) |
How the label says to take it
The US label says to take the tablet in the morning on an empty stomach with up to 4 ounces of plain water, swallow it whole, and wait at least 30 minutes before eating, drinking or taking other medicines by mouth[1]. Your pharmacist can go through this with you.
The trials behind it
Blood-sugar and weight trials of oral semaglutide, with results for both groups, design limits and funding.
Study: PIONEER 1[6]
Does daily oral semaglutide lower blood sugar compared with placebo in early type 2 diabetes?
- Who was in it
- 703 adults with type 2 diabetes managed with diet and exercise alone
- What they got
- Oral semaglutide 3, 7 or 14 mg once a day
- Compared with
- Placebo
- How long
- 26 weeks
- What happened
- HbA1c, compared with placebo: −0.6, −0.9 and −1.1 percentage points (3, 7, 14 mg). Weight, compared with placebo: −0.1, −0.9 and −2.3 kg.
- Limits
- 26 weeks
- Early diabetes only, no active comparator
- Strict fasting dosing rules may differ from daily life
- Funded by
- Novo Nordisk
Summary by Joshua Nichvolodoff, from the published paper — not written by the study's authors. Clinical review: not yet reviewed by a clinician.
Study: OASIS 1[7]
Does daily oral semaglutide 50 mg cause weight loss compared with placebo in adults with obesity or overweight and no diabetes?
- Who was in it
- 667 adults without type 2 diabetes, BMI 30 or more, or 27 or more with complications
- What they got
- Oral semaglutide increased to 50 mg once a day, with lifestyle intervention
- Compared with
- Placebo, with lifestyle intervention
- How long
- 68 weeks
- What happened
- Average weight change: −15.1% vs −2.4% on placebo. Stomach-related side effects: 80% vs 46%.
- Limits
- Tested 50 mg — not the 25 mg dose that was later approved
- People with diabetes were excluded
- Funded by
- Novo Nordisk
Summary by Joshua Nichvolodoff, from the published paper — not written by the study's authors. Clinical review: not yet reviewed by a clinician.
Study: OASIS 4[8]
Does daily oral semaglutide 25 mg — the approved Wegovy pill dose — cause weight loss compared with placebo?
- Who was in it
- 307 adults without diabetes, BMI 30 or more, or 27 or more with an obesity-related complication
- What they got
- Oral semaglutide 25 mg once a day, with lifestyle intervention
- Compared with
- Placebo, with lifestyle intervention
- How long
- 64 weeks to the main results
- What happened
- Average weight change: −13.6% vs −2.2% on placebo. Stomach-related side effects: 74.0% vs 42.2%.
- Limits
- Small (307 people)
- People with diabetes were excluded
- No heart-outcome results of its own
- Funded by
- Novo Nordisk
Summary by Joshua Nichvolodoff, from the published paper — not written by the study's authors. Clinical review: not yet reviewed by a clinician.
Related
Semaglutide · Wegovy · Ozempic
General information, not medical advice. Which product and dose is right for you is a decision for you and your prescriber. Light Years earns nothing from any product named here.
Log each dose and see when the next one is due, on your device. Open my tracker or browse the other guides.
Sources
- RYBELSUS and OZEMPIC (semaglutide) tablets — prescribing information. U.S. Food and Drug Administration (FDALabel), January 2026. https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/27f15fac-7d98-4114-a2ec-92494a91da98/spl-doc. Accessed November 2, 2026. Back to the text
- WEGOVY (semaglutide) injection and WEGOVY tablets — prescribing information. U.S. Food and Drug Administration (FDALabel), June 2026. https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/ee06186f-2aa3-4990-a760-757579d8f77b/spl-doc. Accessed November 2, 2026. Back to the text
- NDA 218316 approval letter — Wegovy (semaglutide) tablets. U.S. Food and Drug Administration, December 22, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/218316Orig1s000ltr.pdf. Accessed November 2, 2026. Back to the text
- Rybelsus (semaglutide tablets) product monograph. Health Canada Drug Product Database / Novo Nordisk Canada, July 13, 2026. https://pdf.hres.ca/dpd_pm/00085311.PDF. Accessed November 2, 2026. Back to the text
- Wegovy weight-loss pill and Canada. Global News, December 24, 2025. https://globalnews.ca/news/11590292/wegovy-weight-loss-pill-canada. Accessed November 2, 2026. Back to the text
- PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care, September 2019. https://pubmed.ncbi.nlm.nih.gov/31186300/ · DOI 10.2337/dc19-0749 · PMID 31186300. Accessed November 2, 2026. Back to the text
- Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1). The Lancet, August 26, 2023. https://pubmed.ncbi.nlm.nih.gov/37385278/ · DOI 10.1016/S0140-6736(23)01185-6 · PMID 37385278. Accessed November 2, 2026. Back to the text
- Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). New England Journal of Medicine, September 18, 2025. https://pubmed.ncbi.nlm.nih.gov/40934115/ · DOI 10.1056/NEJMoa2500969 · PMID 40934115. Accessed November 2, 2026. Back to the text
Figures marked “as reported” are historical: they show what the source said on that date, not today's price or rule.
Changes to this page
- — First published.
Substantive corrections are also logged at corrections.